このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

脳卒中生存者と介護者のための MyStroke

2026年11月6日 更新者:Christopher Favilla、University of Pennsylvania

脳卒中生存者と介護者のための個別化されたビデオベースの脳卒中教育プラットフォーム

The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:

  1. Does a personalized, video-based educational platform improve stroke knowledge?
  2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?
  3. Do different strategies of nudging improve engagement with educational material after hospital discharge?

In order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:

  1. Receive standard education during the stroke hospitalization
  2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.
  3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.
  4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.

調査の概要

状態

まだ募集していません

介入・治療

詳細な説明

Stroke education represents a unique opportunity to empower stroke survivors (and caregivers) to promote self-management, augment adherence, and reduce post-stroke healthcare utilization. Despite being a key quality metric for stroke centers, most patient and caregiver education is poorly retained and a common source of dissatisfaction. In fact, most survivors are unaware of the cause of their stroke, their modifiable risk factors, and how to properly respond to future stroke symptoms. Although there is no gold standard, most centers rely on a combination of bedside verbal communication and standardized printed materials. Prior work has clarified that effective and durable educational interventions benefit from engaging content, personalization, accessibility, and low cost/burden. Retention is very poor during the stroke hospitalization, but this can be overcome by promoting ongoing engagement after discharge.

To that end, our group developed a web-based educational platform (MyStroke) that leverages the electronic health record to personalize video-based educational content for each stroke survivor. Simple but engaging videos are curated to address each patient's stroke etiology, individualized risk factors, prescribed stroke prevention medications, and post-stroke lifestyle issues. This approach transforms point-of-care stroke education, and integrated nudges reveal opportunities for re-education and re-engagement after hospital discharge to achieve a durable impact. In a recent single-center pilot trial, MyStroke improved patient and caregiver satisfaction and improved key elements of stroke knowledge. The objective of this proposal is to build upon our encouraging preliminary experience and conduct a multicenter randomized trial to evaluate the impact of MyStroke on both patient-centered (stroke knowledge, self-efficacy, satisfaction, quality of life) and health system-centered outcomes (medication adherence and health system utilization).

Electronic nudges will leverage principles of behavioral economics (i.e. enhanced nudges) to promote ongoing engagement. Our preliminary data indicate that even bland nudges promote engagement, but here we propose to use both bland nudges and enhanced nudges, such that platform analytics will compare the influence of different nudge types. Use of technology in this context stands to bridge geographic distances, connect stakeholders, and increase access to information, but it important to recognize the potential to exacerbate inequities for elderly patients and those with limited access to technology. Issues of digital inclusivity will be evaluated to reveal opportunities for platform improvement. The MyStroke platform offers a scalable solution stroke education which imposes no burden on the clinical team due to its reliance on a limited number of input fields which can be harvested from the electronic health record to individualized content for each patient.

研究の種類

介入

入学 (推定)

690

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Pennsylvania
      • Lancaster、Pennsylvania、アメリカ、17602
      • Philadelphia、Pennsylvania、アメリカ、19104
      • Philadelphia、Pennsylvania、アメリカ、19104
        • The Hospital of the University of Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
      • West Chester、Pennsylvania、アメリカ、19380
        • Chester County Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • At least 18 years old
  • Admitted to hospital with clinical diagnosis of acute ischemic stroke (imaging confirmation not required)
  • Stroke symptom onset within 30 days of enrollment
  • Being discharged to either home or an acute rehabilitation facility
  • Access to internet enabled device (smartphone, tablet, computer)
  • Fluent in either English or Spanish (does not need to be native or primary language)
  • Willingness and ability to sign informed consent

Exclusion Criteria:

  • Severe aphasia (score of ≥2 on NIHSS item 9)
  • Ischemic stroke that is attributed to a surgical procedure
  • Resides in a skilled nursing facility prior to admission
  • Being discharged to skilled nursing facility or long-term acute care facility
  • Unwillingness or inability to participate in remote/virtual study visits
  • A terminal or advanced condition that raises the possibility the subject may not survive 90 days
  • Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Standard stroke education

Participants in this arm of the study will receive institutional standard stroke education during the course of the hospitalization, standardized across the 5 participating sites. Standard education consists of non-standardized verbal bedside education by the care team, a standardized stroke educational booklet, and standardized verbal instructions by the bedside nurse addressing stroke risk factors and medications.

実験的:MyStroke + standard stroke education

Participants in this arm of the study will receive institutional standard stroke education in addition to access to MyStroke, a personalized video-based education platform. Each participant will receive their personalized page via email or SMS, as per their preference, and they will receive automated nudges to visit educational material after hospital discharge.

MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The Stroke Patient Education Retention (SPER) survey
時間枠:90 days

Total score from the 5-question SPER (scale 0-10; higher score reflects better knowledge)

90 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Patient satisfaction with stroke education
時間枠:90 days

5-point Likert-scale (Q: I am satisfied with the quality of my stroke education; Answers range from strongly disagree to strongly agree)

90 days
Stroke etiology awareness
時間枠:90 days

The proportion of patients who correctly identify their stroke etiology (multiple choice)

90 days
Stroke risk factor awareness
時間枠:90 days

The proportion of patients who correctly identify at least one of their vascular risk factors (select all that apply)

90 days
Antithrombotic medication awareness
時間枠:90 days

The proportion of patients who correctly identify all prescribed antithrombotic medications (free response)

90 days
Stroke Self-Efficacy Questionnaire (SSEQ)
時間枠:90 days

Total score from the 13 item questionnaire (each item scored 0-10; total score 0-130; higher scores represent higher levels of self-efficacy)

90 days
EuroQoL EQ-5D-5L
時間枠:90 days

A standardized measure of health-related quality of life across 5 domains. Each domain is scored using a 5-point ordinal scale (1-5), and the Level Sum Score (LSS) is calculated as the sum of the 5 scores (LSS range is 5-25, lower scores represent higher quality of life).

90 days
Medication adherence
時間枠:90 days

This will be assessed based on pharmacy record review to quantify the Proportion of Days Covered (PDC). PDC is calculated by dividing the number of days with medications available by the total number of days in question (scored between 0 - 1; higher numbers represent more favorable adherence)

90 days
Emergency Department utilization
時間枠:90 days

The number of Emergency Room visits will be summed in the first 90 days following hospital discharge

90 days
Urgent outpatient visits
時間枠:90 days

The number of urgent outpatient visits with primary care and neurologist will be summed in the first 90 days following hospital discharge

90 days
Outpatient provider communication
時間枠:90 days

The number of communications with primary care or neurology providers via telephone or provider communication apps will be summed in the first 90 days following hospital discharge

90 days

その他の成果指標

結果測定
メジャーの説明
時間枠
The Stroke Patient Education Retention (SPER) survey (7 days)
時間枠:7 days

Total score from the 5-question SPER (scale 0-10; higher score reflects better knowledge)

7 days
Patient satisfaction with stroke education (7 days)
時間枠:7 days

5-point Likert-scale (Q: I am satisfied with the quality of my stroke education; Answers range from strongly disagree to strongly agree)

7 days
Stroke etiology awareness (7 days)
時間枠:7 days

The proportion of patients who correctly identify their stroke etiology (multiple choice)

7 days
Stroke risk factor awareness (7 days)
時間枠:7 days

The proportion of patients who correctly identify at least one of their vascular risk factors (select all that apply)

7 days
Antithrombotic medication awareness (7 days)
時間枠:7 days

The proportion of patients who correctly identify all prescribed antithrombotic medications (free response)

7 days
Stroke Self-Efficacy Questionnaire (SSEQ) (7 days)
時間枠:7 days

Total score from the 13 item questionnaire (each item scored 0-10; total score 0-130; higher scores represent higher levels of self-efficacy)

7 days
EuroQoL EQ-5D-5L (7 days)
時間枠:7 days

A standardized measure of health-related quality of life across 5 domains. Each domain is scored using a 5-point ordinal scale (1-5), and the Level Sum Score (LSS) is calculated as the sum of the 5 scores (LSS range is 5-25, lower scores represent higher quality of life).

7 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Christopher G Favilla, MD、Assistant Professor of Neurology at the University of Pennsylvania

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2029年11月30日

研究の完了 (推定)

2030年3月1日

試験登録日

最初に提出

2024年5月29日

QC基準を満たした最初の提出物

2024年5月29日

最初の投稿 (実際)

2024年6月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年1月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Once a manuscript describing such data is accepted for publication, the deidentified dataset contributing to the publication will be shared publicly using the figshare repository (figshare.com). The availability of shared derived data will be described in publications and presentation.

IPD 共有時間枠

We anticipate final sharing of data will take place at the completion of the 5-year project, but if an interim analysis results in a publication, the dataset will be shared at that time-point.

IPD 共有アクセス基準

The data will be publicly available and searchable on figshare (figshare.com), and the availability of shared derived data will be described in publications and presentation.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する